Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Mar 15, 2022
- Accession no.
- 0001209191-22-019019
- Filed
- Mar 15, 2022
- Trade date
- Mar 11-15, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.18M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2022 | Class A Common Stock | CConversionAcquired | +100,000 | $0.00F2 | $0 | 334,020 | Direct | |
| Mar 11, 2022 | Class A Common Stock | SSaleDisposed | −100,000 | $6.95F4 | −$695,000 | 234,020 | Direct | |
| Mar 14, 2022 | Class A Common Stock | CConversionAcquired | +230,000 | $0.00F2 | $0 | 464,020 | Direct | |
| Mar 14, 2022 | Class A Common Stock | SSaleDisposed | −230,000 | $6.28F5 | −$1,444,400 | 234,020 | Direct | |
| Mar 15, 2022 | Class A Common Stock | CConversionAcquired | +6,150 | $0.00F2 | $0 | 240,170 | Direct | |
| Mar 15, 2022 | Class A Common Stock | SSaleDisposed | −6,150 | $6.08F6 | −$37,392 | 234,020 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2022 | Class A Common Stock | CConversionDisposed | −7,258,484 | $0.00F2 | $0 | 7,258,484 | Direct | |
| Mar 14, 2022 | Class A Common Stock | CConversionDisposed | −7,028,484 | $0.00F2 | $0 | 7,028,484 | Direct | |
| Mar 15, 2022 | Class A Common Stock | CConversionDisposed | −7,022,334 | $0.00F2 | $0 | 7,022,334 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.
- F4
This transaction was executed in multiple trades at prices ranging from $6.72 to $7.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $6.065 to $6.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $5.83 to $6.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price
Referenced by the price of 1 transaction in Table I.